134 related articles for article (PubMed ID: 34483284)
1. Effect of Urea Cream on Hand-Foot Syndrome in Patients Receiving Chemotherapy: A Meta-analysis.
Lan TC; Tsou PH; Tam KW; Huang TW
Cancer Nurs; 2022 Sep-Oct 01; 45(5):378-386. PubMed ID: 34483284
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.
Pandy JGP; Franco PIG; Li RK
Support Care Cancer; 2022 Nov; 30(11):8655-8666. PubMed ID: 35655045
[TBL] [Abstract][Full Text] [Related]
3. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
4. Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Lee YS; Jung YK; Kim JH; Cho SB; Kim DY; Kim MY; Kim HJ; Seo YS; Yoon KT; Hong YM; Lee JH; Lee HW; Yim HJ; Jang BK; Jang ES; Jang JY; Hwang SY
Eur J Cancer; 2020 Nov; 140():19-27. PubMed ID: 33039810
[TBL] [Abstract][Full Text] [Related]
5. Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).
Iimura Y; Furukawa N; Ishibashi M; Ahiko Y; Tanabe T; Aikou S; Shida D; Nojima M; Kuroda S; Boku N
BMC Gastroenterol; 2022 Jul; 22(1):341. PubMed ID: 35836104
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial.
Lu W; Huang Z; Chen S; Lv H; Chen X; Lei J; Ke C; Hong C; Wei Y; Su R; Chen R; Sun Z; Yang P; Tan X; Liu H
Ann Palliat Med; 2021 Mar; 10(3):3009-3017. PubMed ID: 33849091
[TBL] [Abstract][Full Text] [Related]
7. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
[TBL] [Abstract][Full Text] [Related]
8. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: a systematic review.
Chen M; Zhang L; Wang Q; Shen J
PLoS One; 2013; 8(8):e72245. PubMed ID: 23977264
[TBL] [Abstract][Full Text] [Related]
9. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy agents: a meta-analysis.
Lian S; Zhang X; Zhang Y; Zhao Q
Clin Exp Dermatol; 2021 Jun; 46(4):629-635. PubMed ID: 33190278
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic and therapeutic efficacy of pyridoxine supplements in the management of hand-foot syndrome during chemotherapy: a meta-analysis.
Jo SJ; Shin H; Jo S; Kwon O; Myung SK
Clin Exp Dermatol; 2015 Apr; 40(3):260-70. PubMed ID: 25557587
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis - systematic review and Bayesian network meta-analysis.
Ramasubbu MK; Maji S; Padhan M; Maiti R; Hota D; Majumdar SKD; Srinivasan A
BMJ Support Palliat Care; 2022 Dec; ():. PubMed ID: 36564149
[TBL] [Abstract][Full Text] [Related]
12. Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).
Santhosh A; Kumar A; Pramanik R; Gogia A; Prasad CP; Gupta I; Gupta N; Cheung WY; Pandey RM; Sharma A; Batra A
Trials; 2022 May; 23(1):420. PubMed ID: 35590388
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and Meta-analysis on the association between Hand-Foot Syndrome (HFS) and Cancer Chemotherapy Efficacy.
Falcone G; Arrigoni C; Dellafiore F; Gallucci F; Milani V; Boveri S; Ausili D; Caruso R
Clin Ter; 2019; 170(5):e388-e395. PubMed ID: 31612198
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological prevention strategy for capecitabine-induced hand-foot syndrome: A network meta-analysis of randomized control trials.
Kao YS; Lo CH; Tu YK; Hung CH
Dermatol Ther; 2022 Oct; 35(10):e15774. PubMed ID: 36054263
[TBL] [Abstract][Full Text] [Related]
15. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Ren Z; Zhu K; Kang H; Lu M; Qu Z; Lu L; Song T; Zhou W; Wang H; Yang W; Wang X; Yang Y; Shi L; Bai Y; Guo X; Ye SL
J Clin Oncol; 2015 Mar; 33(8):894-900. PubMed ID: 25667293
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis.
Huang J; Ye S; Feng S; Zheng M; Zhong M
Int J Colorectal Dis; 2023 Mar; 38(1):61. PubMed ID: 36872385
[TBL] [Abstract][Full Text] [Related]
17. Effect of Extra-Virgin Olive Oil on Hand Foot Syndrome and hs-CRP in Patients Receiving Capecitabine: A Randomized Trial.
Andayani YD; Saleh MI; Sudoyo AW; Ali Z; Legiran L; Partan RU; Yuristo E; Lubis FZ
Acta Med Indones; 2023 Oct; 55(4):396-402. PubMed ID: 38213043
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: A meta-analysis.
Zhou Y; Peng L; Li Y; Chen L
Biomed Rep; 2013 Nov; 1(6):873-878. PubMed ID: 24649045
[TBL] [Abstract][Full Text] [Related]
19. Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabine-Induced Hand-Foot Syndrome: Results of a Prospective Randomized Phase III Study.
Ostwal V; Kapoor A; Mandavkar S; Chavan N; Gupta T; Mirani J; Saklani A; Desouza A; Murugan K; Nashikkar C; Gupta S; Ramaswamy A
Oncologist; 2020 Dec; 25(12):e1886-e1892. PubMed ID: 32717127
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxine Is Effective for Preventing Hand-Foot Syndrome Induced by Pegylated Liposomal Doxorubicin for Multiple Myeloma: The Results of a Randomized Study.
Xiaozhe L; Meilan C; Beihui H; Junru L; Jingli G; Lifen K; Juan L
Integr Cancer Ther; 2022; 21():15347354221140402. PubMed ID: 36510385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
